Statute Details
- Title: Health Products (Medical Devices) Regulations 2010
- Act Code: HPA2007-S436-2010
- Type: Subsidiary legislation (SL)
- Enabling Act (context): Health Products Act (HPA) 2007
- Status: Current version (as at 27 Mar 2026)
- Key subject matter: Regulation of manufacture, import, supply, presentation, advertisement, registration, and post-market obligations for medical devices
- Commencement: Not provided in the extract (see official legislative timeline for exact date)
- Part I: Preliminary (including definitions)
- Notable provisions (from extract): s 2 (definitions); Part IA (licences for manufacture/import); Part III (supply and exceptions); Part IV–V (presentation and advertisement controls); Part VI (registration and evaluation); Part VIII (duties, record-keeping, reporting, enforcement)
- Schedules: Diseases/conditions for advertising restrictions; classification of medical devices; implantable medical devices (and other repealed schedules)
- Related legislation (listed): Dental Registration Act 1999; Health Products Act; Healthcare Services Act 2020; Human Biomedical Research Act 2015
What Is This Legislation About?
The Health Products (Medical Devices) Regulations 2010 (“MD Regulations”) is Singapore’s core regulatory framework for medical devices. In plain terms, it sets out when and how medical devices may be manufactured, imported, supplied, advertised, and registered—along with the compliance duties that manufacturers, importers, wholesalers, suppliers, and registrants must meet.
The Regulations operate as a risk-management system. Medical devices are not treated uniformly; instead, the regulatory intensity depends on device class and intended use (for example, whether it is for “professional use only”, “trained user only”, clinical research, or emergency use). The Regulations also create a structured set of exceptions for activities that would otherwise require licences or registration—such as custom-made devices, devices undergoing maintenance or repair, export-related transactions, and certain phased implementation arrangements.
For practitioners, the MD Regulations are particularly important because they connect pre-market controls (licensing and registration) with post-market obligations (record-keeping, defect/adverse effect reporting, recall and field safety corrective action reporting). This means compliance is not limited to obtaining approvals; it extends into ongoing monitoring and reporting once devices are in the market.
What Are the Key Provisions?
1) Definitions and foundational scope (Part I)
The Regulations begin with standard preliminary provisions, including definitions (s 2). These definitions are critical because they determine whether a product is a “medical device”, who is a “manufacturer/importer/wholesaler/supplier/registrant”, and what counts as “supply”, “advertisement”, or “presentation”. In practice, disputes often arise at the threshold: whether a product falls within the regulatory definition and therefore triggers licensing, registration, labelling, and advertising restrictions.
2) Licensing for manufacture and import (Part IA)
Part IA introduces requirements for the issue of a manufacturer’s licence (s 2A) and an importer’s licence (s 2B). The practical effect is that entities that manufacture or import medical devices for supply in Singapore generally must hold the relevant licence, unless a specific exception applies. The licensing regime is designed to ensure that only competent and accountable entities participate in the medical device supply chain.
3) Manufacture and import without a licence—controlled exceptions (Part II)
Part II provides circumstances where medical devices may be manufactured or imported without a licence. The extract highlights several categories, including: manufacture of medical devices (s 3); manufacture for clinical research (s 3A); manufacture of laboratory-developed tests (s 3B); manufacture of Class A devices for charitable purposes (s 3C); manufacture of specified dental medical devices (s 3D); and import for personal use (s 4A), import of devices licensed under the Radiation Protection Act (s 4B), and import for clinical research (s 4C).
These provisions matter because they define the boundaries of lawful “off-licence” activity. A practitioner advising a hospital, research sponsor, dental clinic, or charitable organisation must map the proposed activity to the correct exception and ensure that the conditions are satisfied. Where conditions are not met, the activity may become an offence or trigger enforcement action.
4) Supply controls, unregistered devices, and exceptions (Part III)
Part III is central to day-to-day commercial compliance. It includes: wholesale supply licensing requirements (s 4D); wholesaling of self-manufactured devices (s 5); and wholesaling of devices in special contexts such as radiation-licensed devices (s 5A) and devices for clinical research (s 5B).
The Regulations also address “unregistered medical devices” through a structured set of exceptions (Division 2). The extract lists exceptions for custom-made devices (s 6), devices after maintenance/repair (s 7), devices for patients’ use (s 8), export or re-export (s 9), non-clinical use (s 10), clinical research (s 10A), and Class A devices (s 10B). There are also provisions for phased implementation of prohibition (s 11) and other exceptions (Division 2A), such as import by a licensed manufacturer without an importer’s licence (s 11A) and wholesale to ships or aircraft by a licensed importer without a wholesaler’s licence (s 11B).
For practitioners, the key takeaway is that “unregistered” does not automatically mean unlawful. Instead, the legality depends on whether the transaction fits within an exception. This is particularly relevant for distributors, parallel importers, research supply chains, and cross-border logistics.
5) Presentation and advertisement restrictions (Parts IV and V)
Parts IV and V regulate how medical devices are presented and advertised to the public and/or professionals. Part IV includes requirements on trade descriptions (s 14), information to be provided with medical devices (s 15), general labelling provisions (s 16), and substantiation of claims about uniqueness and prominence (s 17). It also provides corrective measures where trade descriptions contravene requirements (s 18).
Part V governs advertisement (s 19) and requires substantiation for uniqueness/prominence claims (s 20). It also restricts advertisements for “professional use only” medical devices (s 21) and limits advertisements promoting medical devices for specified diseases and conditions (s 22), supported by a schedule listing the relevant diseases/conditions. The Authority’s power to require copies of advertisements is included (s 23).
In practice, these provisions affect marketing teams, regulatory affairs, and legal counsel. Claims must be supportable, labelling and information must meet statutory requirements, and disease/condition advertising must be carefully reviewed against the schedule and the statutory restrictions.
6) Registration and evaluation (Part VI)
Part VI establishes the registration framework. It includes assignment of medical devices into classes (s 24), requirements for registration (s 25), and an evaluation process (s 26). There is also a prescribed time for cancellation of registration for non-payment of a retention fee (s 26A).
Registration is a major compliance milestone. It determines which devices can be supplied lawfully (subject to exceptions) and triggers ongoing duties for registrants. Practitioners should treat registration as both a legal permission and a continuing compliance obligation, particularly because non-payment can lead to cancellation and because post-market duties apply to ensure safety and performance.
7) Post-market duties, record-keeping, and reporting (Part VIII)
Part VIII is one of the most operationally significant parts of the Regulations. It sets duties and obligations for manufacturers, importers, suppliers, and registrants. The extract highlights:
- Compliance with enforcement orders (s 31) and licence/registration conditions (s 32).
- Specific duties for manufacturers (s 33), importers (s 34), and wholesalers (s 35).
- Information duties for suppliers of unregistered Class A medical devices (s 35A).
- Safety and performance compliance (s 36) and duties of sponsors (s 36A).
- Offence for contravention of duties (s 37).
- Record-keeping: manufacture records (s 38), supply records (s 39), and additional clinical research records (ss 39A–39B).
- Qualified practitioners maintaining records of implantable medical devices (s 40).
- Complaint records (s 41).
- Reporting: defects and adverse effects (s 42), information adversely affecting quality/safety/efficacy (s 43), recall notifications (ss 44–45), and field safety corrective action notifications (ss 46–47).
- Change management: changes affecting licence (s 48) and changes concerning registered medical devices (s 49).
This suite of provisions is designed to ensure that once a device is in the market, the regulatory system can detect and respond to risks quickly. For counsel, these duties are often the basis for regulatory investigations, enforcement actions, and liability assessments after incidents.
How Is This Legislation Structured?
The Regulations are organised into Parts that track the medical device lifecycle:
Part I (Preliminary) contains citation/commencement and definitions.
Part IA sets licensing requirements for manufacturers and importers.
Part II provides controlled circumstances for manufacture and import without a licence.
Part III regulates supply, including wholesaler licensing, and provides exceptions for unregistered devices (with additional divisions for other exceptions and supply requirements). It also includes a specific emergency medical device exception (Part IIIA).
Part IV addresses presentation and labelling/trade description requirements.
Part V addresses advertisement restrictions and substantiation requirements.
Part VI provides the registration framework, including classification, evaluation, and retention fee cancellation.
Part VII concerns certificates (with some provisions deleted in the current version).
Part VIII sets duties and obligations, including record-keeping and reporting, and provides for offences for contraventions.
Part X (Miscellaneous) includes notices to the Authority, confidentiality, revocation, and savings/transitional provisions.
Schedules support the framework, including disease/condition lists for advertising restrictions, device classification, and implantable medical devices.
Who Does This Legislation Apply To?
The MD Regulations apply to persons and entities involved in the medical device supply chain in Singapore, including manufacturers, importers, wholesalers, suppliers, registrants, and (in specified contexts) qualified practitioners responsible for implantable devices. The obligations differ depending on role: manufacturers and importers face licensing and specific duties; suppliers and registrants face supply, safety, and compliance duties; and practitioners may have record-keeping obligations for implantables.
The Regulations also apply to activities such as clinical research and charitable or emergency use, but legality depends on whether the activity fits within the relevant exception (for example, clinical research manufacture/supply exceptions, emergency medical device provisions, and Class A device exceptions). Accordingly, applicability is not only about who the actor is, but also about what the actor is doing and for what intended purpose.
Why Is This Legislation Important?
For practitioners, the MD Regulations are important because they translate the Health Products regulatory policy into concrete legal duties across the device lifecycle. The combination of licensing/registration controls and post-market reporting obligations creates a comprehensive compliance environment. A breach can lead to enforcement action, including cancellation of registration (for retention fee non-payment), regulatory orders, and potential offences under the Regulations.
From a risk perspective, Part VIII’s reporting and record-keeping duties are particularly significant. They require systems for defect/adverse effect reporting, recall and field safety corrective action notifications, and complaint handling. These requirements are often the difference between a timely regulatory response and a delayed or inadequate one after an incident.
From a commercial perspective, Parts IV and V affect marketing and communications. Claims about uniqueness, prominence, and disease/condition relevance must be substantiated and must comply with restrictions on advertising—especially where devices are for “professional use only” or where advertising is limited for specified diseases and conditions. Legal review of labelling and promotional materials is therefore a practical necessity.
Related Legislation
- Health Products Act (HPA) 2007
- Healthcare Services Act 2020
- Human Biomedical Research Act 2015
- Dental Registration Act 1999
Source Documents
This article provides an overview of the Health Products (Medical Devices) Regulations 2010 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.